AstraZeneca announced a new collaboration with Cancer Research UK to launch a center of excellence in genetic screening, cancer modeling and big data processing aimed at accelerating the discovery of new cancer medicines.
According to the drugmaker, the Functional Genomics Centre will further develop CRISPR technology to better understand the biology of cancer, creating biological models that may be more reflective of human disease, and advancing computational approaches to better analyze big datasets.
The center will be located at the Milner Therapeutics Institute at the University of Cambridge. Scientists will have access to the next generation of CRISPR libraries for silencing or activating every gene in the genome, accessed through an extension of the existing collaboration between AstraZeneca and the Wellcome Sanger Institute.
Read the press release
[javascriptSnippet]
